Literature DB >> 26304712

Radiofrequency catheter ablation of ventricular arrhythmias originating from the continuum between the aortic sinus of Valsalva and the left ventricular summit: Electrocardiographic characteristics and correlative anatomy.

Chin-Yu Lin1, Fa-Po Chung1, Yenn-Jiang Lin1, Eric Chong2, Shih-Lin Chang1, Li-Wei Lo1, Yu-Feng Hu1, Ta-Chuan Tuan1, Tze-Fan Chao1, Jo-Nan Liao1, Yao-Ting Chang1, Yun-Yu Chen3, Chun-Ku Chen4, Chuen-Wang Chiou1, Shih-Ann Chen5, Hsuan-Ming Tsao6.   

Abstract

BACKGROUND: Radiofrequency ablation of ventricular arrhythmias (VAs) originating from the continuum between the aortic sinus of Valsalva (ASV) and the left ventricular (LV) summit is a challenge.
OBJECTIVES: The objectives of this study were to investigate the electrocardiographic, electrophysiological, and anatomical characteristics of VAs and to develop an algorithm for predicting the successful ablation site.
METHODS: We recruited 66 patients (mean age, 47 ± 15 years; 42 male patients) with symptomatic VAs originating from the continuum between the ASV and the LV summit who underwent radiofrequency ablation. Patients were classified into 4 groups (group 1: ASV, n = 20; group 2: subvalvular region, n = 15; group 3: great cardiac vein/anterior interventricular vein [GCV/AIV], n = 16; group 4: epicardium requiring pericardial access, n = 15). The QRS morphological characteristics of VAs were compared between the 4 groups.
RESULTS: Electrocardiographic analysis revealed that the aVL/aVR Q-wave ratio is useful in the prediction of successful ablation sites in the ASV, subvalvular area, GCV/AIV, and epicardium requiring pericardial access at cutoff values of ≤1.415, 1.416-1.535, 1.536-1.740, and >1.740, respectively. The aVL/aVR Q-wave ratio was well correlated with the distance between the successful ablation site and the tip of the LV summit. A distance of >18.9 mm and an LV myocardial thickness of >9.1 mm predicted the need for the epicardial or GCV/AIV approaches. There were no major procedural complications. Eight patients (12.1%) developed VA recurrence during a mean follow-up of 15.9 months (interquartile range 9.2-24.2 months).
CONCLUSION: The aVL/aVR Q-wave ratio is a useful parameter for predicting the successful ablation sites of VAs originating from the continuum between the ASV and the LV summit.
Copyright © 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ablation; Aortic sinus of Valsalva; Electrocardiography; Left ventricular summit; Ventricular arrhythmia

Mesh:

Year:  2015        PMID: 26304712     DOI: 10.1016/j.hrthm.2015.08.030

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  12 in total

1.  Retrograde Coronary Venous Ethanol Infusion for Ablation of Refractory Ventricular Tachycardia.

Authors:  Bahij Kreidieh; Moisés Rodríguez-Mañero; Paul Schurmann; Sergio Hugo Ibarra-Cortez; Amish S Dave; Miguel Valderrábano
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-07

Review 2.  Conventional mapping and ablation of focal ventricular tachycardias in the healthy heart.

Authors:  Sonia Busch; Johannes Brachmann; Ahmed Saleh; Mathias Forkmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-05-08

3.  Pathological autopsy of a patient that underwent a successful ablation of an electrical storm from the left ventricular summit.

Authors:  Yuichi Hori; Shiro Nakahara; Sohtaro Mine; Naofumi Anjo; Akiko Fujii; Yoshihiko Ueda; Isao Taguchi
Journal:  Heart Vessels       Date:  2016-05-13       Impact factor: 2.037

Review 4.  Alcohol Ablation for Ventricular Tachycardia.

Authors:  Adi Lador; Akanibo Da-Wariboko; Liliana Tavares; Miguel Valderrábano
Journal:  Methodist Debakey Cardiovasc J       Date:  2021-03-25

5.  Non-fluoroscopic catheter ablation of arrhythmias with origin at the summit of the left ventricle.

Authors:  Santiago Rivera; Nicolás Vecchio; Paz Ricapito; Felix Ayala-Paredes
Journal:  J Interv Card Electrophysiol       Date:  2019-02-07       Impact factor: 1.900

6.  A High-Precision Deep Learning Algorithm to Localize Idiopathic Ventricular Arrhythmias.

Authors:  Ting-Yung Chang; Ke-Wei Chen; Chih-Min Liu; Shih-Lin Chang; Yenn-Jiang Lin; Li-Wei Lo; Yu-Feng Hu; Fa-Po Chung; Chin-Yu Lin; Ling Kuo; Shih-Ann Chen
Journal:  J Pers Med       Date:  2022-05-09

7.  Predicting the Origin of Ventricular Arrhythmia Using Acoustic Cardiography.

Authors:  Chin-Yu Lin; Shih-Lin Chang; Yenn-Jiang Lin; Li-Wei Lo; Yu-Feng Hu; Tze-Fan Chao; Fa-Po Chung; Ta-Chuan Tuan; Jo-Nan Liao; Yao-Ting Chang; Abigail Louise D Te; Shinya Yamada; Hao-Min Cheng; Shih-Hsien Sung; Ling Kuo; Hsing-Yuan Li; Ting-Yung Chang; Hoang Quang Minh; Simon Salim; Ting-Chung Huang; Shih-Ann Chen
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

8.  The use of a novel signal analysis to identify the origin of idiopathic right ventricular outflow tract ventricular tachycardia during sinus rhythm: Simultaneous amplitude frequency electrogram transformation mapping.

Authors:  Abigail Louise D Te; Satoshi Higa; Fa-Po Chung; Chin-Yu Lin; Men-Tzung Lo; Che-An Liu; Chen Lin; Yi-Chung Chang; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Ta-Chuan Tuan; Tze-Fan Chao; Jonan Liao; Yao-Ting Chang; Chung-Hsing Lin; Yuan Hung; Shinya Yamada; Kuo-Li Pan; Yenn-Jiang Lin; Shih-Ann Chen
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

9.  Safety and Efficacy of Epicardial Ablation of Ventricular Tachyarrhythmias: Experience from a Tertiary Referral Center in Taiwan.

Authors:  Chin-Yu Lin; Fa-Po Chung; Yenn-Jiang Lin; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Jo-Nan Liao; Ta-Chuan Tuan; Tze-Fan Chao; Yao-Ting Chang; Yun-Yu Chen; Abigail Louise D Te; Shinya Yamada; Shih-Ann Chen
Journal:  Acta Cardiol Sin       Date:  2018-01       Impact factor: 2.672

10.  Chemical ablation of ventricular tachycardia arising from the left ventricular summit.

Authors:  Kaoru Okishige; Rena Nakamura; Yasuteru Yamauchi; Takehiko Keida; Tetsuo Sasano; Kenzo Hirao
Journal:  Clin Case Rep       Date:  2019-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.